AssetMark Inc
ORIC icon

AssetMark Inc’s Oric Pharmaceuticals ORIC Stock Holding History

AssetMark Inc’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38K Hold
3,000
– – ﹤0.01% 1841
2025
Q4 		$24.5K Sell
3,000
-89
-3% -$1.02K ﹤0.01% 1938
2025
Q3 		$37.1K Buy
+3,089
New +$32.5K ﹤0.01% 1734

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

AssetMark Inc's ORIC Position: Q1 2026 in Review

AssetMark Inc held its Oric Pharmaceuticals (ORIC) position steady in Q1 2026 at 3,000 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #1841.

AssetMark Inc first reported a position in ORIC in Q3 2025 and has held it in 3 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • AssetMark Inc held 3,000 shares of Oric Pharmaceuticals worth $38K as of Q1 2026.
  • AssetMark Inc left its Oric Pharmaceuticals share count unchanged in Q1 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #1841 holding.
  • AssetMark Inc first reported a position in Oric Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.